DrugPatentWatch Database Preview
VIIV Company Profile
What is the competitive landscape for VIIV, and what generic alternatives to VIIV drugs are available?
VIIV has nineteen approved drugs.
There are seventeen US patents protecting VIIV drugs.
There are eight hundred and sixty-three patent family members on VIIV drugs in sixty-seven countries and one hundred and twenty-six supplementary protection certificates in fifteen countries.
Summary for VIIV
| International Patents: | 863 |
| US Patents: | 17 |
| Tradenames: | 12 |
| Ingredients: | 12 |
| NDAs: | 19 |
| Patent Litigation for VIIV: | See patent lawsuits for VIIV |
| PTAB Cases with VIIV as patent owner: | See PTAB cases with VIIV as patent owner |
Drugs and US Patents for VIIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | TIVICAY | dolutegravir sodium | TABLET;ORAL | 204790-003 | Jun 9, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-001 | Aug 6, 2007 | RX | Yes | No | 7,368,460 | ➤ Sign Up | ➤ Sign Up | ||||
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | SOLUTION;ORAL | 020978-001 | Dec 17, 1998 | AA | RX | Yes | Yes | 6,641,843*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | TABLET;ORAL | 020977-001 | Dec 17, 1998 | AB | RX | Yes | Yes | 6,294,540*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Viiv Hlthcare | JULUCA | dolutegravir sodium; rilpivirine hydrochloride | TABLET;ORAL | 210192-001 | Nov 21, 2017 | RX | Yes | Yes | 8,080,551 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for VIIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 4,828,838*PED | ➤ Sign Up |
| Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | 5,047,407*PED | ➤ Sign Up |
| Viiv Hlthcare | EPIVIR | lamivudine | SOLUTION;ORAL | 020596-001 | Nov 17, 1995 | 5,047,407*PED | ➤ Sign Up |
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | TABLET;ORAL | 020977-001 | Dec 17, 1998 | 5,034,394*PED | ➤ Sign Up |
| Viiv Hlthcare | ZIAGEN | abacavir sulfate | SOLUTION;ORAL | 020978-001 | Dec 17, 1998 | 5,034,394*PED | ➤ Sign Up |
| Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | 4,828,838 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
| ➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
| ➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
| ➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
| ➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
| ➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
| ➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
| ➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
| ➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
Non-Orange Book US Patents for VIIV
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,273,065 | Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors | ➤ Sign Up |
| 8,841,310 | Combinations of a pyrimidine containing NNRTI with RT inhibitors | ➤ Sign Up |
| 7,217,714 | CCR5 modulators | ➤ Sign Up |
| 7,638,522 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino] benzonitrile | ➤ Sign Up |
| 8,410,103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | ➤ Sign Up |
| 7,108,864 | Tablet formation | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for VIIV Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Netherlands | 300676 | ➤ Sign Up |
| Taiwan | 536403 | ➤ Sign Up |
| Japan | WO2007049675 | ➤ Sign Up |
| Malaysia | 156920 | ➤ Sign Up |
| Denmark | 1789139 | ➤ Sign Up |
| Slovakia | 8762001 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for VIIV Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2012000035 | Germany | ➤ Sign Up | PRODUCT NAME: RILPIVIRIN UND DESSEN STEREOCHEMISCH ISOMERE FORMEN, SOWIE DESSEN PHARMAZEUTISCH UNBEDENKLICHE ADDITIONSSALZE, EINSCHLIESSLICH DES CHLORWASSERSTOFFSAEURESALZES VON RILPIVIRIN; REGISTRATION NO/DATE: EU/1/11/736/001 20111128 |
| 2012 00021 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ET FARMACEUTISK ACCEPTABELT ADDITIONSSALT AF RILPIVIRIN, HERUNDER HYDROCHLORID ADDITIONSSALTET AF RILPIVIRIN, OG TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128 |
| 2016044 | Lithuania | ➤ Sign Up | PRODUCT NAME: RILPIVIRINAS + EMTRICITABINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| 2016043 | Lithuania | ➤ Sign Up | PRODUCT NAME: RILPIVIRINO HIDROCHLORIDAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| 2008006,C0933372 | Lithuania | ➤ Sign Up | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| 1419152/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: RILPIVIRIN; REGISTRATION NO/DATE: SWISSMEDIC 61548 26.02.2013 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
